Promega Biotech India Private Ltd. and CORE Diagnostics, India Enter into Technology Collaboration

New Delhi, August 26, 2018: Promega Biotech India Private Ltd., a 100% subsidiary of Promega Corporation USA, a leader in providing innovative solutions and technical support to the life sciences industry, has entered into a technology collaboration with CORE Diagnostics. The collaboration allows CORE Diagnostics to leverage Automated Nucleic Acid Purification with Promega Integrated Quantitation systems. The Maxwell® Automated Nucleic Acid Purification Instrument offers bench top automation with worry-free, walk-away purification of DNA and RNA from a variety of different sample types.

The collaboration agreement focuses on the implementation of the Promega Microsatellite Instability (MSI) technology for Immuno-Oncology. The patent-protected MSI technology is considered the gold standard molecular assay for detecting DNA mismatch-repair deficiency.

“We are very pleased that CORE diagnostics and Promega have entered into a collaboration,” said Dr. Rajnish Bharti, General Manager at Promega India. “Following our recent discussions with a number of labs, it is clear that they view the Promega MSI assay as an important tool for determining DNA mismatch repair deficiency that is a more straightforward measurement relative to next-generation sequencing. We strongly believe that Promega technologies will be adding substantial value to CORE Diagnostics.”

Zoya Brar, Founder and Managing Director, CORE Diagnostics, added, “In modern medical science, the role of state-of –the-art diagnostic tools such as nucleic acid purification is of utmost importance and plays a critical role in selecting the most effective clinical intervention. We are constantly innovating in all aspects of service delivery in underserved high-end diagnostics market. We are excited to partner with a global leader in the field of biochemistry, genomics and molecular biology which will help us adapt and be able to scale our capabilities to automating the current sample processing and expand our network to make the high-end techniques available to Indian healthcare market in the best possible way.”

Gurgaon-based CORE Diagnostics brings latest cutting edge testing techniques in areas of definitive diagnosis and Molecular Diagnostics, Flow Cytometry, Immunohistochemistry, Histopathology, Cytogenetics and Cytopathology for the patients in India. These tests bring targeted, customized treatment one step closer to reality and can help the health practitioners provide the most actionable information to address the various treatment needs of patients in India to get better outcomes.

Corporate Comm India(CCI Newswire)